CELC
Celcuity Inc.
NASDAQ · Healthcare · Biotechnology · US
$96.01
−0.44%Price chart
Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−25.4x
Market Cap
$4.70B
MomentumView details →
1D Return
−0.44%
YTD Return
−5.03%
RSI (14)
53.1
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−25.4x
Market Cap
$4.70B
RSI (14)
53.1
MomentumView details →
1D Return
−0.44%
YTD Return
−5.03%
SummaryUpdated Jun 1, 2026
Celcuity Inc. (NASDAQ:CELC) is a clinical-stage biotechnology company founded in 2011 and headquartered in Minneapolis, Minnesota. The company went public in September 2017 and focuses on developing molecularly targeted cancer therapies. Celcuity operates through two main platforms: its lead drug candidate <b>gedatolisib</b>, which targets multiple cancer pathways simultaneously, and its proprietary <b>CELsignia diagnostic platform</b> that uses living tumor cells to identify specific cellular processes driving individual patients' cancers. The company is currently in late-stage clinical trials with potential regulatory approval on the horizon for 2025-2026.
Similar companies
Latest newsMore news →
Celcuity Inc. submitted a supplemental New Drug Application to the U.S. Food and Drug Administration for REVTORPYK (gedatolisib) to treat HR+/HER2-, PIK3CA mutant locally advanced or metastatic breast cancer.9d agoBrandywine Managers LLC acquired a new stake in Celcuity, Inc. (NASDAQ: CELC) during the second quarter, purchasing 6,621 shares valued at approximately $693,000, as disclosed in a recent SEC filing.10d agoCelcuity Inc. launched REVTORPYK (gedatolisib) commercially following FDA approval and NCCN Category 1 inclusion.21d ago